The 2013 ACC/AHA cholesterol guidelines had no significant change in lipid testing behavior, which can be potentially attributed to the varying cholesterol treatment guidelines implemented by organizations, said Sara Levintow, PhD candidate, Department of Epidemiology at the University of North Carolina at Chapel Hill.
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines had no significant change in lipid testing behavior, which can be potentially attributed to the varying cholesterol treatment guidelines implemented by organizations, said Sara Levintow, PhD candidate, Department of Epidemiology at the University of North Carolina at Chapel Hill.
Transcript
There was considerable attention to the 2013 change in the ACC/AHA cholesterol guidelines, yet you found no real change in testing behavior. How can we account for this?
We studied the frequency of [low-density lipoprotein] cholesterol testing frequency from before to after the release of the 2013 guidelines and those revised guidelines did remove the recommendation of ongoing LDL testing in order to treat patients to blood cholesterol goals. As you noted, we found very little, if any impact of the guidelines on LDL testing frequency following the release of the guidelines. So, this could be due to lack of awareness or understanding among physicians. It’s also possible that given that physicians are faced with a multitude of cholesterol treatment guidelines from varying organizations, sometimes or historically there are conflicts between those guidelines. There could also be disagreement or perhaps confusion over which guideline to follow, therefore leading to unchanged rates of LDL testing as observed in our study.
Were there any distinct population subgroups that stood out in the study, such as less testing among seniors, or less testing among younger adults? Any regional differences?
We did overall find that rates of LDL testing were unchanged and we explored multiple diverse patient populations including patients who were initiating statins at varying intensities, patients who were starting acetamide, as well as patients who are at much higher cardiovascular risk—those who had recent hospitalizations for myocardial infarction or ischemic stroke. In general, our findings were consistent. I will say that overall over the course of the study period, generally adults who were older, who had more higher levels of risk for cardiovascular disease, did have lower rates of testing. That was in contrast to younger adults who are at lower risk of cardiovascular disease who in general had higher rates of testing.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More